within the rapidly evolving discipline of cancer therapeutics, knowing the intricate mechanisms of Antibody-Drug Conjugates (ADCs) is vital for building productive treatments. One of the most promising approaches is the usage of in vitro bystander impact assays, which play a pivotal purpose in improving therapeutic efficacy. These assays, supplied